Company: Dr. Reddy's Laboratories Ltd. Category: Company News


The audit of Research and Development facility of Aurigene Discovery Technologies Limited, a wholly owned subsidiary, situated at Hyderabad by the USFDA, has been completed on March 21, 2019.
March 25, 2019, 8:49 a.m.

In July, 2018, Indivior through a court injunction had block Dr Reddys generic version of Suboxone Film.
March 12, 2019, 9:03 a.m.

Shares of Dr Reddy's Laboratories were trading at Rs 2,640 per scrip on BSE, up 2.11 per cent from their previous close
Feb. 22, 2019, 1:25 p.m.

Such recalls are for dangerous or defective products that predictably can cause serious health problems
Feb. 21, 2019, 3:20 p.m.


The potential revenue upside from the sale of generic Suboxone is expected to be substantial for Dr Reddy's when it resumes sales
Feb. 20, 2019, 5:27 p.m.

This site was included in the warning letter received from the USFDA in November 2015.
Feb. 18, 2019, 9:31 a.m.

This is the second plant to come out of the warning letter after multiple inspections conducted by the US drug regulator
Feb. 16, 2019, 9:34 p.m.

This site was included in the warning letter received from the USFDA in November 2015.
Feb. 16, 2019, 6:38 p.m.

The site was again audited in October 2018, Dr Reddy's said.
Feb. 16, 2019, 5:05 p.m.

United Healthcare Services, Inc, filed a complaint against Dr. Reddy's Laboratories alleging an overarching price-fixing conspiracy to rig bids and allocate customers with respect to 30 drugs.
Feb. 6, 2019, 4:21 p.m.

-->